CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 407 enrolled
Drug / intervention
tiotropium-bromidedrug
Likely dose
tiotropium-bromide 18 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00613574
NCT00613574N/ACompleted
CompareCT.gov

RUSSE / Russian Spiriva® Safety & Efficacy Study

Boehringer Ingelheim·observational·Posted Feb 13, 2008·Updated Apr 10, 2014

In Brief

An observational study evaluating tiotropium-bromide for COPD. Completed, enrolled 407 participants across 33 sites.

Detailed Summary

At the moment, there is hardly any structured safety and efficacy data collection on Tiotropium in Russia. Therefore, the objective of this observational study is to collect and evaluate data on bronchodilator efficacy and safety of Spiriva® (18 µg tiotropium inhalation capsules) delivered by HandiHaler®, in a national sample of Russian patients with varying severities of chronic obstructive pulmonary disease (COPD) in a real life setting over the 8 weeks.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsCOPD
CountriesRussia
Collaborators--

Timeline

N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 13, 2008
Study CompletionOct 1, 2007
TodayJul 2, 2026
Posted 18.4 years ago

Interventions

tiotropium-bromidedrug

Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care